MedTrace Logo

RCT of Methotrexate Added to Treatment As Usual in Schizophrenia

NCT02074319 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2015-09-22

No results posted yet for this study

Summary

The aim of the this study is to evaluate the effectiveness of methotrexate added to treatment as usual on positive and negative symptoms, cognitive and social functioning and quality of life of patients suffering from schizophrenia.

Conditions

  • Schizophrenia
  • Schizoaffective Disorder
  • Schizophreniform Disorder

Interventions

DRUG

Methotrexate

Treatment as usual or standard treatment for psychosis will be common in all arms

Sponsors & Collaborators

  • Abbasi Shaheed Hospital

    collaborator OTHER

  • Dow University of Health Sciences

    collaborator OTHER

  • Karwan e Hayat, Karachi, Pakistan

    collaborator UNKNOWN

  • Institute of Behavioural Sciences, Karachi, Pakistan

    collaborator UNKNOWN

  • Pakistan Institute of Living and Learning

    lead OTHER

Principal Investigators

  • Prof Imran B Chaudhry, MD · University of Manchester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-07-31
Completion
2015-08-31

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02074319 on ClinicalTrials.gov